{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:52:23Z","timestamp":1790704343495,"version":"4.1.0"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,1]]},"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n To summarise the extent and type of evidence in relation to adverse events (AEs) associated with the use of cannabis-based products (CBP) in people living with cancer.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The Joanna Briggs Institute (JBI) methodology for scoping reviews was applied. A search was performed in MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCOhost), Scopus, Web of Science Core Collections and AMED (Ovid) from their inception to 7 May 2023. Primary studies reporting AEs associated with any form of natural or synthetic CBP use in any cancer care setting and location were included.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n One hundred fifty-two studies were included, with the most prevalent being randomised controlled trials (RCTs) (n<\/jats:italic>\u2009=\u200961), followed by non-randomised controlled trials (n<\/jats:italic>\u2009=\u200926) and case reports (n<\/jats:italic>\u2009=\u200923). CBP was mainly used in gastrointestinal, liver, or peritoneal cancer (n<\/jats:italic>\u2009=\u200998) and haematological or lymphoid cancer (n<\/jats:italic>\u2009=\u200992), primarily to manage nausea and vomiting (n<\/jats:italic>\u2009=\u200978) and cancer pain (n<\/jats:italic>\u2009=\u200937). The most common CBP ingredients were combinations of THC and CBD (n<\/jats:italic>\u2009=\u200969), synthetic THC (n<\/jats:italic>\u2009=\u200947), single compounds of THC (n<\/jats:italic>\u2009=\u200942) and CBD (n<\/jats:italic>\u2009=\u200916) with diverse forms, administration routes and doses. The primary methods of administration were oral (n<\/jats:italic>\u2009=\u200994) and inhalation (n<\/jats:italic>\u2009=\u200954). A broad range of AEs were reported; the most common were related to the nervous system (n<\/jats:italic>\u2009=\u2009118), psychiatric (n<\/jats:italic>\u2009=\u2009101) and gastrointestinal system (n<\/jats:italic>\u2009=\u200981). Diverse patient characteristics, significant under-reporting and low-quality reporting were observed in many studies.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n More rigorous research designs that prioritise comprehensive, standardised reporting of AEs and CBP use are required to fully elucidate the safety profile of CBP use in cancer care.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00520-024-09087-w","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T22:11:09Z","timestamp":1734559869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adverse events associated with the use of cannabis-based products in people living with cancer: a systematic scoping review"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9288-4151","authenticated-orcid":false,"given":"Irene","family":"Cheah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6109-9134","authenticated-orcid":false,"given":"Jennifer","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3961-2288","authenticated-orcid":false,"given":"Ingrid","family":"Gelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2548-6030","authenticated-orcid":false,"given":"Wai-Jo Jocelin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-2144","authenticated-orcid":false,"given":"Joanna E.","family":"Harnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"9087_CR1","doi-asserted-by":"crossref","first-page":"153473542210817","DOI":"10.1177\/15347354221081772","volume":"21","author":"DI Abrams","year":"2022","unstructured":"Abrams DI (2022) Cannabis, Cannabinoids and cannabis-based medicines in cancer care. Integr Cancer Ther 21:15347354221081772","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"9087_CR2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3747\/co.25.3983","volume":"25","author":"K Martell","year":"2018","unstructured":"Martell K, Fairchild A, LeGerrier B, Sinha R, Baker S, Liu H et al (2018) Rates of cannabis use in patients with cancer. Curr Oncol 25(3):219\u2013225","journal-title":"Curr Oncol"},{"issue":"24","key":"9087_CR3","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.3390\/cancers15245822","volume":"15","author":"I Osaghae","year":"2023","unstructured":"Osaghae I, Chido-Amajuoyi OG, Khalifa BAA, Talluri R, Shete S (2023) Cannabis use among cancer survivors: use pattern, product type, and timing of use. Cancers (Basel) 15(24):5822","journal-title":"Cancers (Basel)"},{"issue":"5","key":"9087_CR4","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/dar.13444","volume":"41","author":"L Mills","year":"2022","unstructured":"Mills L, Lintzeris N, O\u2019Malley M, Arnold JC, McGregor IS (2022) Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. Drug Alcohol Rev 41(5):1095\u20131108","journal-title":"Drug Alcohol Rev"},{"key":"9087_CR5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2017.35.31_suppl.245","volume":"35","author":"YD Chang","year":"2017","unstructured":"Chang YD, Smith JS, Oberoi-Jassal R, Desai V, Winn SL, Portman D et al (2017) Cannabis use in palliative care: the prevalence and clinical characteristics. Am Soc Clin Oncol 35:245","journal-title":"Am Soc Clin Oncol"},{"issue":"10","key":"9087_CR6","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1089\/jpm.2018.0533","volume":"22","author":"KA Donovan","year":"2019","unstructured":"Donovan KA, Chang YD, Oberoi-Jassal R, Rajasekhara S, Smith J, Haas M et al (2019) Relationship of cannabis use to patient-reported symptoms in cancer patients seeking supportive\/palliative care. J Palliat Med 22(10):1191\u20131195","journal-title":"J Palliat Med"},{"issue":"2","key":"9087_CR7","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ijrobp.2017.06.042","volume":"99","author":"K Tringale","year":"2017","unstructured":"Tringale K, Shi Y, Hattangadi J (2017) Marijuana utilization in Cancer patients: a comprehensive analysis of National Health and nutrition examination survey data from 2005\u20132014. Int J Radiat Oncol Biol Phys 99(2):S11","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"9087_CR8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1534735411423920","volume":"11","author":"M Horneber","year":"2011","unstructured":"Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2011) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11(3):187\u2013203","journal-title":"Integr Cancer Ther"},{"key":"9087_CR9","unstructured":"DISA. Marijuana Legality by State 2024 [cited 18 May 2024]. Available from: https:\/\/disa.com\/marijuana-legality-by-state"},{"key":"9087_CR10","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2022 National Survey on Drug Use and Health. HHS publication no. PEP23\u201307\u201301\u2013006 2023: Rockville, MD:\u00a0Center for behavioral health statistics and quality, substance abuse and mental health services administration; [cited 18 May 2024]. Available from: https:\/\/www.samhsa.gov\/data\/"},{"key":"9087_CR11","doi-asserted-by":"publisher","unstructured":"National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington (DC): National Academies Press (US) 2017 Jan 12 [Available from: https:\/\/doi.org\/10.17226\/24625","DOI":"10.17226\/24625"},{"issue":"2","key":"9087_CR12","first-page":"85","volume":"19","author":"I Turgeman","year":"2017","unstructured":"Turgeman I, Bar-Sela G (2017) Cannabis use in palliative oncology: a review of the evidence for popular indications. Isr Med Assoc J 19(2):85\u201388","journal-title":"Isr Med Assoc J"},{"issue":"4","key":"9087_CR13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s13311-015-0370-x","volume":"12","author":"D Gloss","year":"2015","unstructured":"Gloss D (2015) An overview of products and bias in research. Neurotherapeutics 12(4):731\u2013734","journal-title":"Neurotherapeutics"},{"issue":"1","key":"9087_CR14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00482-015-0083-4","volume":"30","author":"J Ablin","year":"2016","unstructured":"Ablin J, Ste-Marie PA, Sch\u00e4fer M, H\u00e4user W, Fitzcharles MA (2016) Medical use of cannabis products: lessons to be learned from Israel and Canada. Schmerz 30(1):3\u201313","journal-title":"Schmerz"},{"key":"9087_CR15","unstructured":"National Conference of State Legislatures. State Medical Cannabis Laws [updated 22 June 2023, cited 07 March 2024]. Available from: https:\/\/www.ncsl.org\/health\/state-medical-cannabis-laws"},{"issue":"1","key":"9087_CR16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/ijms25010074","volume":"25","author":"PP Bathula","year":"2023","unstructured":"Bathula PP, Maciver MB (2023) Cannabinoids in treating chemotherapy-induced nausea and vomiting, cancer-associated pain, and tumor growth. Int J Mol Sci 25(1):74","journal-title":"Int J Mol Sci"},{"issue":"11","key":"9087_CR17","first-page":"Cd009464","volume":"2015","author":"LA Smith","year":"2015","unstructured":"Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015(11):Cd009464","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"9087_CR18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.17305\/bjbms.2018.3532","volume":"19","author":"B Dari\u0161","year":"2019","unstructured":"Dari\u0161 B, Tancer Verboten M, Knez \u017d, Ferk P (2019) Cannabinoids in cancer treatment: therapeutic potential and legislation. Bosn J Basic Med Sci 19(1):14\u201323","journal-title":"Bosn J Basic Med Sci"},{"issue":"7","key":"9087_CR19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.6004\/jnccn.2016.0094","volume":"14","author":"MP Davis","year":"2016","unstructured":"Davis MP (2016) Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Canc Netw 14(7):915\u2013922","journal-title":"J Natl Compr Canc Netw"},{"key":"9087_CR20","doi-asserted-by":"crossref","unstructured":"Peters MDJ, Godfrey CMP, Munn Z, Tricco AC, Khalil H, editors. (2020) Chapter 11: scoping reviews (2020 version). In: Aromataris E, Munn Z (Editors). JBI Manual for Evid Syn","DOI":"10.46658\/JBIRM-20-01"},{"issue":"7","key":"9087_CR21","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467\u2013473","journal-title":"Ann Intern Med"},{"key":"9087_CR22","unstructured":"Equator Network. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews [updated 10 Nov 2022, cited 16 Feb 2023]. Available from: https:\/\/www.equator-network.org\/reporting-guidelines\/prisma\/"},{"key":"9087_CR23","doi-asserted-by":"crossref","first-page":"102279","DOI":"10.1016\/j.eujim.2023.102279","volume":"62","author":"I Cheah","year":"2023","unstructured":"Cheah I, Gelissen I, Hunter J, Harnett J (2023) Adverse events associated with the use of cannabis-based products in people living with cancer: a scoping review protocol. Eur J Integr Med 62:102279","journal-title":"Eur J Integr Med"},{"key":"9087_CR24","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Post-approval safety data management: definitions and standards for expedited reporting E2D. Step 4 version. Dated 12 November 2003 [cited 16 Feb 2023]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/E2D_Guideline.pdf"},{"key":"9087_CR25","unstructured":"Covidence systematic review software [Internet]. Veritas Health Innovation, Melbourne, Australia. Available from: www.covidence.org"},{"key":"9087_CR26","unstructured":"National Cancer Institute. CTEP cancer therapy evaluation program [updated 19 Apr 2021, cited 12 Mar 2023]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_60"},{"key":"9087_CR27","unstructured":"Microsoft Corporation. Microsoft Excel [Internet]. 2011. Available from: https:\/\/office.microsoft.com\/excel"},{"issue":"23\u201324","key":"9087_CR28","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/0024-3205(95)00194-B","volume":"56","author":"A Abrahamov","year":"1995","unstructured":"Abrahamov A, Mechoulam R (1995) An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56(23\u201324):2097\u20132102","journal-title":"Life Sci"},{"issue":"5","key":"9087_CR29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/bjc.1983.247","volume":"48","author":"S Ahmedzai","year":"1983","unstructured":"Ahmedzai S, Carlyle DL, Calder IT, Moran F (1983) Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48(5):657\u2013663","journal-title":"Br J Cancer"},{"issue":"1","key":"9087_CR30","first-page":"23","volume":"23","author":"D Allen","year":"2019","unstructured":"Allen D (2019) Dronabinol therapy: central nervous system adverse events in adults with primary brain tumors. Clin J Oncol Nurs 23(1):23\u201326","journal-title":"Clin J Oncol Nurs"},{"issue":"4","key":"9087_CR31","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1200\/JOP.18.00562","volume":"15","author":"SP Anderson","year":"2019","unstructured":"Anderson SP, Zylla DM, McGriff DM, Arneson TJ (2019) Impact of medical cannabis on patient-reported symptoms for patients with cancer enrolled in Minnesota\u2019s medical cannabis program. J Oncol Practice 15(4):e338\u2013e345","journal-title":"J Oncol Practice"},{"key":"9087_CR32","doi-asserted-by":"crossref","first-page":"e1285","DOI":"10.1136\/spcare-2022-004003","volume":"13","author":"S Aprikian","year":"2023","unstructured":"Aprikian S, Kasvis P, Vigano M, Hachem Y, Canac-Marquis M, Vigano A (2023) Medical cannabis is effective for cancer-related pain: Quebec Cannabis Registry results. BMJ Supportive Palliat Care 13:e1285","journal-title":"BMJ Supportive Palliat Care"},{"issue":"991822726980667","key":"9087_CR33","volume":"3","author":"J Aviram","year":"2022","unstructured":"Aviram J, Lewitus GM, Vysotski Y, Amna MA, Ouryvaev A, Procaccia S et al (2022) The effectiveness and safety of medical cannabis for treating cancer related symptoms in oncology patients. Front Pain Res (Lausanne, Switzerland) 3(9918227269806676):861037","journal-title":"Front Pain Res (Lausanne, Switzerland)"},{"issue":"12","key":"9087_CR34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/ph13120435","volume":"13","author":"J Aviram","year":"2020","unstructured":"Aviram J, Lewitus GM, Vysotski Y, Uribayev A, Procaccia S, Cohen I et al (2020) Short-term medical cannabis treatment regimens produced beneficial effects among palliative cancer patients. Pharmaceuticals (Basel, Switzerland) 13(12):435","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"9003220","key":"9087_CR35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejim.2018.01.023","volume":"49","author":"L Bar-Lev Schleider","year":"2018","unstructured":"Bar-Lev Schleider L, Mechoulam R, Lederman V, Hilou M, Lencovsky O, Betzalel O et al (2018) Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med 49(9003220):37\u201343","journal-title":"Eur J Intern Med"},{"issue":"9","key":"9087_CR36","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.3390\/cancers12092447","volume":"12","author":"G Bar-Sela","year":"2020","unstructured":"Bar-Sela G, Cohen I, Campisi-Pinto S, Lewitus GM, Oz-Ari L, Jehassi A et al (2020) Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. Cancers 12(9):2447","journal-title":"Cancers"},{"issue":"1","key":"9087_CR37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/CAD.0000000000000685","volume":"30","author":"G Bar-Sela","year":"2018","unstructured":"Bar-Sela G, Tauber D, Mitnik I, Sheinman-Yuffe H, Bishara-Frolova T, Aharon-Peretz J (2018) Cannabis-related cognitive impairment: a prospective evaluation of possible influences on patients with cancer during chemotherapy treatment as a pilot study. Anticancer Drugs 30(1):91\u201397","journal-title":"Anticancer Drugs"},{"issue":"101215021","key":"9087_CR38","first-page":"510392","volume":"2013","author":"G Bar-Sela","year":"2013","unstructured":"Bar-Sela G, Vorobeichik M, Drawsheh S, Omer A, Goldberg V, Muller E (2013) The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients on supportive or palliative care. Evid-Based Complement Altern Med\u202f: eCAM 2013(101215021):510392","journal-title":"Evid-Based Complement Altern Med : eCAM"},{"issue":"101128834","key":"9087_CR39","first-page":"153473541988149","volume":"18","author":"G Bar-Sela","year":"2019","unstructured":"Bar-Sela G, Zalman D, Semenysty V, Ballan E (2019) The effects of dosage-controlled cannabis capsules on cancer-related cachexia and anorexia syndrome in advanced cancer patients: pilot study. Integr Cancer Ther 18(101128834):1534735419881498","journal-title":"Integr Cancer Ther"},{"issue":"9","key":"9087_CR40","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/annonc\/mdq727","volume":"22","author":"TD Brisbois","year":"2011","unstructured":"Brisbois TD, de Kock IH, Watanabe SM, Mirhosseini M, Lamoureux DC, Chasen M et al (2011) Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 22(9):2086\u20132093","journal-title":"Ann Oncol"},{"issue":"10","key":"9087_CR41","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1089\/jpm.2018.0551","volume":"22","author":"C Carr","year":"2019","unstructured":"Carr C, Vertelney H, Fronk J, Trieu S (2019) Dronabinol for the treatment of paraneoplastic night sweats in cancer patients: a report of five cases. J Palliat Med 22(10):1221\u20131223","journal-title":"J Palliat Med"},{"issue":"13","key":"9087_CR42","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1200\/JCO.2007.15.2777","volume":"26","author":"DW Cescon","year":"2008","unstructured":"Cescon DW, Page AV, Richardson S, Moore MJ, Boerner S, Gold WL (2008) Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. J Clin Oncol 26(13):2214\u20132215","journal-title":"J Clin Oncol"},{"issue":"6","key":"9087_CR43","first-page":"946","volume":"79","author":"HS Chan","year":"1987","unstructured":"Chan HS, Correia JA, MacLeod SM (1987) Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 79(6):946\u2013952","journal-title":"Pediatrics"},{"issue":"6","key":"9087_CR44","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/0003-4819-91-6-819","volume":"91","author":"AE Chang","year":"1979","unstructured":"Chang AE, Shiling DJ, Stillman RC (1979) Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Internal Med 91(6):819\u201324","journal-title":"Ann Internal Med"},{"issue":"7","key":"9087_CR45","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/1097-0142(19810401)47:7<1746::AID-CNCR2820470704>3.0.CO;2-4","volume":"47","author":"AE Chang","year":"1981","unstructured":"Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I et al (1981) A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47(7):1746\u20131751","journal-title":"Cancer"},{"issue":"11","key":"9087_CR46","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1007\/s00520-021-06202-z","volume":"29","author":"S Chapman","year":"2021","unstructured":"Chapman S, Protudjer J, Bourne C, Kelly LE, Oberoi S, Vanan MI (2021) Medical cannabis in pediatric oncology: a survey of patients and caregivers. Support Care Cancer 29(11):6589\u20136594","journal-title":"Support Care Cancer"},{"issue":"1","key":"9087_CR47","first-page":"109","volume":"69","author":"ML Citron","year":"1985","unstructured":"Citron ML, Herman TS, Vreeland F, Krasnow SH, Fossieck BE Jr, Harwood S et al (1985) Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 69(1):109\u2013112","journal-title":"Cancer Treat Rep"},{"issue":"10 October","key":"9087_CR48","doi-asserted-by":"crossref","first-page":"e0270543","DOI":"10.1371\/journal.pone.0270543","volume":"17","author":"S Clarke","year":"2022","unstructured":"Clarke S, Butcher BE, McLachlan AJ, Henson JD, Rutolo D, Hall S et al (2022) Pilot clinical and pharmacokinetic study of \u03949-tetrahydrocannabinol (THC)\/cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain. PLoS ONE 17(10 October):e0270543","journal-title":"PLoS ONE"},{"issue":"662","key":"9087_CR49","first-page":"449","volume":"91","author":"BM Colls","year":"1980","unstructured":"Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG (1980) The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N Z Med J 91(662):449\u2013451","journal-title":"N Z Med J"},{"issue":"4","key":"9087_CR50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/0003489415612801","volume":"125","author":"M Cote","year":"2016","unstructured":"Cote M, Trudel M, Wang C, Fortin A (2016) Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Ann Otol Rhinol Laryngol 125(4):317\u2013324","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"1","key":"9087_CR51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02934575","volume":"3","author":"SM Crawford","year":"1986","unstructured":"Crawford SM, Buckman R (1986) Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother 3(1):39\u201342","journal-title":"Med Oncol Tumor Pharmacother"},{"issue":"S1","key":"9087_CR52","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1002\/j.1552-4604.1981.tb02572.x","volume":"21","author":"CM Cronin","year":"1981","unstructured":"Cronin CM, Sallan SE, Gelber R, Lucas VS, Laszlo J (1981) Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. J Clin Pharmacol 21(S1):43S-50S","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"9087_CR53","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0277-5379(88)90300-8","volume":"24","author":"D Cunningham","year":"1988","unstructured":"Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M et al (1988) A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24(4):685\u2013689","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"101128834","key":"9087_CR54","first-page":"153473542110617","volume":"20","author":"S D'Andre","year":"2021","unstructured":"D\u2019Andre S, McAllister S, Nagi J, Giridhar KV, Ruiz-Macias E, Loprinzi C (2021) Topical cannabinoids for treating chemotherapy-induced neuropathy: a case series. Integr Cancer Ther 20(101128834):15347354211061740","journal-title":"Integr Cancer Ther"},{"issue":"JAN","key":"9087_CR55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fonc.2018.00643","volume":"9","author":"PB Dall'Stella","year":"2019","unstructured":"Dall\u2019Stella PB, Docema MFL, Maldaun MVC, Feher O, Lancellotti CLP (2019) Case report: clinical outcome and image response of two patients with secondary high-grade glioma treated with chemoradiation, PCV, and cannabidiol. Front Oncol 9(JAN):643","journal-title":"Front Oncol"},{"issue":"5","key":"9087_CR56","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/adc.61.5.502","volume":"61","author":"AM Dalzell","year":"1986","unstructured":"Dalzell AM, Bartlett H, Lilleyman JS (1986) Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child 61(5):502\u2013505","journal-title":"Arch Dis Child"},{"issue":"4","key":"9087_CR57","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2125.1974.tb00257.x","volume":"1","author":"BH Davies","year":"1974","unstructured":"Davies BH, Weatherstone RM, Graham JDP, Griffiths RD (1974) A pilot study of orally administered \u03941-trans-tetrahydrocannabinol in the management of patients undergoing radiotherapy for carcinoma of the bronchus. Br J Clin Pharmacol 1(4):301\u2013306","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"9087_CR58","first-page":"319","volume":"6","author":"ML Devine","year":"1987","unstructured":"Devine ML, Dow GJ, Greenberg BR (1987) Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study. Clin Pharm 6(4):319\u2013322","journal-title":"Clin Pharm"},{"issue":"1S","key":"9087_CR59","first-page":"81S","volume":"21","author":"RB Diasio","year":"1981","unstructured":"Diasio RB, Ettinger DS, Satterwhite BE (1981) Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations. J Clin Pharmacol 21(1S):81S\u20135S","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"9087_CR60","first-page":"14","volume":"3","author":"GJ Dow","year":"1984","unstructured":"Dow GJ, Meyers FH, Stanton W, Devine ML (1984) Serious reactions to oral delta-9-tetrahydrocannabinol in cancer chemotherapy patients. Clin Pharm 3(1):14","journal-title":"Clin Pharm"},{"issue":"5","key":"9087_CR61","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2125.2010.03743.x","volume":"70","author":"M Duran","year":"2010","unstructured":"Duran M, Perez E, Abanades S, Vidal X, Saura C, Majem M et al (2010) Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 70(5):656\u2013663","journal-title":"Br J Clin Pharmacol"},{"issue":"S1","key":"9087_CR62","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1002\/j.1552-4604.1981.tb02576.x","volume":"21","author":"LH Einhorn","year":"1981","unstructured":"Einhorn LH, Nagy C, Furnas B, Williams SD (1981) Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 21(S1):64S-S69","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"9087_CR63","doi-asserted-by":"crossref","first-page":"657","DOI":"10.5694\/j.1326-5377.1979.tb127271.x","volume":"2","author":"H Ekert","year":"1979","unstructured":"Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P (1979) Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust 2(12):657\u2013659","journal-title":"Med J Aust"},{"issue":"8","key":"9087_CR64","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1007\/s00520-016-3180-8","volume":"24","author":"DA Elliott","year":"2016","unstructured":"Elliott DA, Nabavizadeh N, Romer JL, Chen Y, Holland JM (2016) Medical marijuana use in head and neck squamous cell carcinoma patients treated with radiotherapy. Support Care Cancer 24(8):3517\u20133524","journal-title":"Support Care Cancer"},{"issue":"3","key":"9087_CR65","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/2049463717710042","volume":"11","author":"MT Fallon","year":"2017","unstructured":"Fallon MT, Albert Lux E, McQuade R, Rossetti S, Sanchez R, Sun W et al (2017) Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. Br J Pain 11(3):119\u2013133","journal-title":"Br J Pain"},{"issue":"101652231","key":"9087_CR66","doi-asserted-by":"crossref","first-page":"100820","DOI":"10.1016\/j.gore.2021.100820","volume":"37","author":"J Fehniger","year":"2021","unstructured":"Fehniger J, Brodsky AL, Kim A, Pothuri B (2021) Medical marijuana utilization in gynecologic cancer patients. Gynecol Oncol Rep 37(101652231):100820","journal-title":"Gynecol Oncol Rep"},{"issue":"6","key":"9087_CR67","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-91-6-825","volume":"91","author":"S Frytak","year":"1979","unstructured":"Frytak S, Moertel CG, O\u2019Fallon JR, Rubin J, Creagan ET, O\u2019Connell MJ et al (1979) Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Internal Med 91(6):825\u201330","journal-title":"Ann Internal Med"},{"issue":"12","key":"9087_CR68","first-page":"1427","volume":"68","author":"S Frytak","year":"1984","unstructured":"Frytak S, Moertel CG, Rubin J (1984) Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. Cancer Treat Rep 68(12):1427\u20131431","journal-title":"Cancer Treat Rep"},{"issue":"14","key":"9087_CR69","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/BF01487619","volume":"61","author":"HH Gerhartz","year":"1983","unstructured":"Gerhartz HH, Binsack T, Hiller E (1983) Levonantradol for the treatment of chemotherapy-induced nausea and vomiting. Klin Wochenschr 61(14):719\u2013721","journal-title":"Klin Wochenschr"},{"issue":"11","key":"9087_CR70","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1002\/1097-0142(19951201)76:11<2330::AID-CNCR2820761122>3.0.CO;2-F","volume":"76","author":"CJ Gilbert","year":"1995","unstructured":"Gilbert CJ, Ohly KV, Rosner G, Peters WP (1995) Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. Cancer 76(11):2330\u20132337","journal-title":"Cancer"},{"issue":"5","key":"9087_CR71","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/jpm.2019.0540","volume":"23","author":"PD Good","year":"2020","unstructured":"Good PD, Greer RM, Huggett GE, Hardy JR (2020) An open-label pilot study testing the feasibility of assessing total symptom burden in trials of cannabinoid medications in palliative care. J Palliat Med 23(5):650\u2013655","journal-title":"J Palliat Med"},{"issue":"11","key":"9087_CR72","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","volume":"31","author":"P Grimison","year":"2020","unstructured":"Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P et al (2020) Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol 31(11):1553\u20131560","journal-title":"Ann Oncol"},{"key":"9087_CR73","doi-asserted-by":"crossref","first-page":"7503323","DOI":"10.1111\/bcp.15701","volume":"89","author":"M Guedon","year":"2023","unstructured":"Guedon M, Le Bozec A, Brugel M, Clarenne J, Carlier C, Perrier M et al (2023) Cannabidiol-drug interaction in cancer patients: a retrospective study in a real-life setting. British J Clin Pharmacol 89:7503323","journal-title":"British J Clin Pharmacol"},{"issue":"4","key":"9087_CR74","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.resed.2010.02.002","volume":"17","author":"G Guy","year":"2010","unstructured":"Guy G, Gover J, Rogerson M, Atwell B, Dineen J (2010) Positive data in sativex phase IIb trial: support advancing into phase III development in cancer pain. Revista de la Sociedad Espanola del Dolor 17(4):219\u2013221","journal-title":"Revista de la Sociedad Espanola del Dolor"},{"issue":"2","key":"9087_CR75","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.bjc.6603236","volume":"95","author":"M Guzman","year":"2006","unstructured":"Guzman M, Duarte MJ, Blazquez C, Ravina J, Rosa MC, Galve-Roperh I et al (2006) A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 95(2):197\u2013203","journal-title":"Br J Cancer"},{"issue":"7","key":"9087_CR76","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.22.01632","volume":"41","author":"J Hardy","year":"2023","unstructured":"Hardy J, Greer R, Huggett G, Kearney A, Gurgenci T, Good P (2023) Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). J Clin Oncol 41(7):1444\u20131452","journal-title":"J Clin Oncol"},{"issue":"4","key":"9087_CR77","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.3747\/co.26.4743","volume":"26","author":"P Hawley","year":"2019","unstructured":"Hawley P, Gobbo M (2019) Cannabis use in cancer: a survey of the current state at BC cancer before recreational legalization in Canada. Curr Oncol (Toronto, Ont) 26(4):e425\u2013e432","journal-title":"Curr Oncol (Toronto, Ont)"},{"issue":"S1","key":"9087_CR78","first-page":"86S","volume":"21","author":"ME Heim","year":"1981","unstructured":"Heim ME, Romer W, Queisser W (1981) Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting. J Clin Pharmacol 21(S1):86S-S89","journal-title":"J Clin Pharmacol"},{"issue":"23","key":"9087_CR79","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJM197906073002302","volume":"300","author":"TS Herman","year":"1979","unstructured":"Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC et al (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300(23):1295\u20131297","journal-title":"N Engl J Med"},{"issue":"910","key":"9087_CR80","first-page":"331","volume":"27","author":"TS Herman","year":"1997","unstructured":"Herman TS, Jones SE, Dean J, Leigh S, Dorr R, Moon TE et al (1997) Nabilone: a potent antiemetic cannabinol with minimal euphoria. Biomed \/ [publiee pour l\u2019AAICIG] 27(910):331\u20134","journal-title":"Biomed \/ [publiee pour l'AAICIG]"},{"issue":"dpi, 9433352","key":"9087_CR81","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jocn.2019.11.024","volume":"71","author":"K Hsu","year":"2020","unstructured":"Hsu K, Whitham E, Kichenadasse G (2020) Potential role of cannabidiol for seizure control in a patient with recurrent glioma. J Clin Neurosci 71(dpi, 9433352):275\u20136","journal-title":"J Clin Neurosci"},{"issue":"1","key":"9087_CR82","first-page":"11","volume":"26","author":"A Huniadi","year":"2021","unstructured":"Huniadi A, Sorian A, Iuhas C, Bodog A, Sandor MI (2021) The effect of cannabis in the treatment of hodgkin\u2019s lymphoma in a pregnant patient - extensive case report and literature review. J BUON 26(1):11\u201316","journal-title":"J BUON"},{"issue":"8","key":"9087_CR83","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/0277-5379(83)90032-9","volume":"19","author":"AW Hutcheon","year":"1983","unstructured":"Hutcheon AW, Palmer JB, Soukop M, Cunningham D, McArdle C, Welsh J et al (1983) A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol 19(8):1087\u20131090","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"5","key":"9087_CR84","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/j.jpainsymman.2023.01.002","volume":"65","author":"S Jafri","year":"2023","unstructured":"Jafri S, Hansen E, Fuenmayor R, Case AA (2023) Medical cannabis for insomnia in a patient with advanced breast cancer. J Pain Symptom Manage 65(5):e497\u2013e502","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"9087_CR85","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.2002.20.2.567","volume":"20","author":"A Jatoi","year":"2002","unstructured":"Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20(2):567\u2013573","journal-title":"J Clin Oncol"},{"issue":"2","key":"9087_CR86","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","volume":"39","author":"JR Johnson","year":"2010","unstructured":"Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39(2):167\u2013179","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"9087_CR87","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jpainsymman.2012.07.014","volume":"46","author":"JR Johnson","year":"2013","unstructured":"Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT (2013) An open-label extension study to investigate the long-term safety and tolerability of THC\/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage 46(2):207\u2013218","journal-title":"J Pain Symptom Manage"},{"issue":"Suppl. B","key":"9087_CR88","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0305-7372(82)80035-2","volume":"9","author":"SE Jones","year":"1982","unstructured":"Jones SE, Durant JR, Greco FA, Robertone A (1982) A multi-institutional phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treatment Rev 9(Suppl. B):45\u20138","journal-title":"Cancer Treatment Rev"},{"issue":"1","key":"9087_CR89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00296765","volume":"9","author":"RA Joss","year":"1982","unstructured":"Joss RA, Galeazzi RL, Bischoff A, Do DD, Goldhirsch A, Brunner KW (1982) Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. Cancer Chemother Pharmacol 9(1):61\u201364","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"9087_CR90","doi-asserted-by":"crossref","first-page":"vdab006","DOI":"10.1093\/noajnl\/vdab006","volume":"3","author":"TM Juarez","year":"2021","unstructured":"Juarez TM, Piccioni D, Rose L, Nguyen A, Brown B, Kesari S (2021) Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer. Neuro-oncol Adv 3(1):vdab006","journal-title":"Neuro-oncol Adv"},{"issue":"10","key":"9087_CR91","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.21873\/anticanres.12924","volume":"38","author":"J Kenyon","year":"2018","unstructured":"Kenyon J, Liu W, Dalgleish A (2018) Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. Anticancer Res 38(10):5831\u20135835","journal-title":"Anticancer Res"},{"issue":"3","key":"9087_CR92","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/107327481602300311","volume":"23","author":"S Khwaja","year":"2016","unstructured":"Khwaja S, Yacoub A, Cheema A, Rihana N, Russo R, Velez AP et al (2016) Marijuana smoking in patients with leukemia. Cancer control 23(3):278\u2013283","journal-title":"Cancer control"},{"issue":"6 I","key":"9087_CR93","first-page":"1014","volume":"33","author":"S Kleinman","year":"1983","unstructured":"Kleinman S, Weitzman SA, Cassem N, Andrews E (1983) Double blind trial of delta-9-tetrahydrocannabinol (THC) versus placebo as an adjunct to prochlorperazine for chemotherapy-induced vomiting. Curr Therapeut Res- Clin Exp 33(6 I):1014\u20137","journal-title":"Curr Therapeut Res- Clin Exp"},{"issue":"6","key":"9087_CR94","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1089\/cap.2020.0203","volume":"31","author":"CM Klier","year":"2021","unstructured":"Klier CM, Amminger GP, Kothgassner OD, Laczkovics C, Felnhofer A (2021) Letter to the editor: cannabidiol treatment - is there an effect on cognitive functioning, quality of life, and behavior? A Case Report. J Child Adolesc Psychopharmacol 31(6):447\u2013449","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"9087_CR95","first-page":"338","volume":"21","author":"JC Kluin-Neleman","year":"1979","unstructured":"Kluin-Neleman JC, Neleman FA, Meuwissen OJ, Maes RA (1979) delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo. Vet Hum Toxicol 21(5):338\u2013340","journal-title":"Vet Hum Toxicol"},{"issue":"5","key":"9087_CR96","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jpainsymman.2018.02.004","volume":"55","author":"TS Kutiel","year":"2018","unstructured":"Kutiel TS, Vornicova O, Bar-Sela G (2018) Cannabis for vismodegib-related muscle cramps in a patient with advanced basal cell carcinoma. J Pain Symptom Manage 55(5):e1\u2013e2","journal-title":"J Pain Symptom Manage"},{"issue":"100959882","key":"9087_CR97","first-page":"e45408","volume":"25","author":"CS Lam","year":"2023","unstructured":"Lam CS, Zhou K, Loong HH-F, Chung VC-H, Ngan C-K, Cheung YT (2023) The use of traditional, complementary, and integrative medicine in cancer: data-mining study of 1 million web-based posts from health forums and social media platforms. J Med Int Res 25(100959882):e45408","journal-title":"J Med Int Res"},{"issue":"6","key":"9087_CR98","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00000421-199012000-00006","volume":"13","author":"M Lane","year":"1990","unstructured":"Lane M, Smith FE, Sullivan RA, Plasse TF (1990) Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. Am J Clin Oncol 13(6):480\u2013484","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"9087_CR99","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/0885-3924(91)90026-Z","volume":"6","author":"M Lane","year":"1991","unstructured":"Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J et al (1991) Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 6(6):352\u2013359","journal-title":"J Pain Symptom Manage"},{"issue":"S1","key":"9087_CR100","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1002\/j.1552-4604.1981.tb02573.x","volume":"21","author":"J Laszlo","year":"1981","unstructured":"Laszlo J, Lucas VS Jr, Hanson DC, Cronin CM, Sallan SE (1981) Levonantradol for chemotherapy-induced emesis: phase I-II oral administration. J Clin Pharmacol 21(S1):51S-S56","journal-title":"J Clin Pharmacol"},{"issue":"S1","key":"9087_CR101","doi-asserted-by":"crossref","first-page":"103S","DOI":"10.1002\/j.1552-4604.1981.tb02583.x","volume":"21","author":"M Levitt","year":"1981","unstructured":"Levitt M, Wilson A, Bowman D, Kemel S, Krepart G, Marks V et al (1981) Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. J Clin Pharmacol 21(S1):103S-S109","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"9087_CR102","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1503\/cmaj.150847","volume":"188","author":"AM Li","year":"2016","unstructured":"Li AM, Rassekh SR (2016) Hypotension associated with ingestion of cannabinoids in two children with cancer. CMAJ 188(8):596\u2013597","journal-title":"CMAJ"},{"issue":"2","key":"9087_CR103","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jpainsymman.2017.09.001","volume":"55","author":"AH Lichtman","year":"2018","unstructured":"Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W et al (2018) Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage 55(2):179\u201388.e1","journal-title":"J Pain Symptom Manage"},{"issue":"12","key":"9087_CR104","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jama.1980.03300380021014","volume":"243","author":"VS Lucas Jr","year":"1980","unstructured":"Lucas VS Jr, Laszlo J (1980) delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA 243(12):1241\u20131243","journal-title":"JAMA"},{"issue":"6","key":"9087_CR105","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0009-9260(82)80383-8","volume":"33","author":"HH Lucraft","year":"1982","unstructured":"Lucraft HH, Palmer MK (1982) Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clin Radiol 33(6):621\u2013622","journal-title":"Clin Radiol"},{"issue":"1","key":"9087_CR106","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpainsymman.2013.02.018","volume":"47","author":"ME Lynch","year":"2014","unstructured":"Lynch ME, Cesar-Rittenberg P, Hohmann AG (2014) A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage 47(1):166\u2013173","journal-title":"J Pain Symptom Manage"},{"issue":"9","key":"9087_CR107","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/COC.0000000000000718","volume":"43","author":"DM Macari","year":"2020","unstructured":"Macari DM, Gbadamosi B, Jaiyesimi I, Gaikazian S (2020) Medical cannabis in cancer patients: a survey of a community hematology oncology population. Am J Clin Oncol 43(9):636\u2013639","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"9087_CR108","doi-asserted-by":"crossref","first-page":"e20193256","DOI":"10.1542\/peds.2019-3256","volume":"145","author":"K Madden","year":"2020","unstructured":"Madden K, Tanco K, Bruera E (2020) Clinically significant drug-drug interaction between methadone and cannabidiol. Pediatrics 145(6):e20193256","journal-title":"Pediatrics"},{"issue":"6","key":"9087_CR109","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1089\/jpm.2008.9880","volume":"11","author":"V Maida","year":"2008","unstructured":"Maida V (2008) Nabilone for the treatment of paraneoplastic night sweats: a report of four cases. J Palliat Med 11(6):929\u2013934","journal-title":"J Palliat Med"},{"issue":"1","key":"9087_CR110","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jpainsymman.2016.09.003","volume":"53","author":"V Maida","year":"2017","unstructured":"Maida V (2017) Medical cannabis in the palliation of malignant wounds-a case report. J Pain Symptom Manage 53(1):e4\u2013e6","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"9087_CR111","first-page":"119","volume":"6","author":"V Maida","year":"2008","unstructured":"Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M (2008) Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Supportive Oncol 6(3):119\u2013124","journal-title":"J Supportive Oncol"},{"key":"9087_CR112","doi-asserted-by":"crossref","unstructured":"Marchese M, Zhu C, Charbonneau LF, Peragine C, De Angelis C. Description and disposition of patients with cancer accessing a novel, pharmacist-led cannabis consultation service. JCO Oncology Practice. 2022;313((Marchese, Charbonneau, Peragine, De Angelis) Department of Pharmacy, Sunnybrook Odette Cancer Centre, Toronto, Canada(Marchese, Zhu, De Angelis) Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada(De Angelis) Sunnybrook Research Instit):00748","DOI":"10.1200\/OP.21.00748"},{"issue":"3","key":"9087_CR113","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF00175407","volume":"6","author":"M McCabe","year":"1988","unstructured":"McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS (1988) Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 6(3):243\u2013246","journal-title":"Invest New Drugs"},{"issue":"3","key":"9087_CR114","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1185\/030079907X167525","volume":"23","author":"E Meiri","year":"2007","unstructured":"Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang H-M et al (2007) Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23(3):533\u2013543","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"9087_CR115","first-page":"354","volume":"58","author":"P Mekavuthikul","year":"2020","unstructured":"Mekavuthikul P, Phuditshinnapatra J, Chomchai S (2020) Cannabis oil could provoke secondary myocardial infarction in a high-risk patient after dropping into both ear and sublingual administration: a case report. Clin Toxicol 58(4):354","journal-title":"Clin Toxicol"},{"issue":"6","key":"9087_CR116","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/10428194.2021.2020776","volume":"63","author":"CM Melen","year":"2022","unstructured":"Melen CM, Merrien M, Wasik AM, Panagiotidis G, Beck O, Sonnevi K et al (2022) Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia. Leuk Lymphoma 63(6):1387\u20131397","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"9087_CR117","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1188\/18.CJON.438-443","volume":"22","author":"S Merkle","year":"2018","unstructured":"Merkle S, Tavernier SS (2018) Cannabis use and bleomycin: an overview and case study of pulmonary toxicity. Clin J Oncol Nurs 22(4):438\u2013443","journal-title":"Clin J Oncol Nurs"},{"issue":"S1","key":"9087_CR118","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1002\/j.1552-4604.1981.tb02571.x","volume":"21","author":"JA Neidhart","year":"1981","unstructured":"Neidhart JA, Gagen MM, Wilson HE, Young DC (1981) Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol 21(S1):38S-42S","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"9087_CR119","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/082585979401000105","volume":"10","author":"K Nelson","year":"1994","unstructured":"Nelson K, Walsh D, Deeter P, Sheehan F (1994) A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 10(1):14\u201318","journal-title":"J Palliat Care"},{"issue":"8","key":"9087_CR120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF01728184","volume":"64","author":"N Niederle","year":"1986","unstructured":"Niederle N, Schutte J, Schmidt CG (1986) Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 64(8):362\u2013365","journal-title":"Klin Wochenschr"},{"issue":"11","key":"9087_CR121","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1007\/s00520-022-07312-y","volume":"30","author":"SW Nielsen","year":"2022","unstructured":"Nielsen SW, Hasselsteen SD, Dominiak HSH, Labudovic D, Reiter L, Dalton SO et al (2022) Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy. Support Care Cancer 30(11):9441\u20139451","journal-title":"Support Care Cancer"},{"issue":"2","key":"9087_CR122","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00520-021-06515-z","volume":"30","author":"SW Nielsen","year":"2022","unstructured":"Nielsen SW, Ruhlmann CH, Eckhoff L, Bronnum D, Herrstedt J, Dalton SO (2022) Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences. Supportive Care Cancer 30(2):1181\u20131190","journal-title":"Supportive Care Cancer"},{"issue":"4","key":"9087_CR123","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00000421-198508000-00013","volume":"8","author":"A Niiranen","year":"1985","unstructured":"Niiranen A, Mattson K (1985) A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 8(4):336\u2013340","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"9087_CR124","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00000421-198708000-00014","volume":"10","author":"A Niiranen","year":"1987","unstructured":"Niiranen A, Mattson K (1987) Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol 10(4):325\u2013329","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"9087_CR125","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/cpt197518184","volume":"18","author":"R Noyes Jr","year":"1975","unstructured":"Noyes R Jr, Brunk SF, Avery DA, Canter AC (1975) The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18(1):84\u201389","journal-title":"Clin Pharmacol Ther"},{"issue":"2\u20133","key":"9087_CR126","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/j.1552-4604.1975.tb02348.x","volume":"15","author":"R Noyes Jr","year":"1975","unstructured":"Noyes R Jr, Brunk SF, Baram DA, Canter A (1975) Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 15(2\u20133):139\u2013143","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"9087_CR127","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/08880018.2019.1630537","volume":"36","author":"R Ofir","year":"2019","unstructured":"Ofir R, Bar-Sela G, Weyl Ben-Arush M, Postovsky S (2019) Medical marijuana use for pediatric oncology patients: single institution experience. Pediatr Hematol Oncol 36(5):255\u2013266","journal-title":"Pediatr Hematol Oncol"},{"issue":"11","key":"9087_CR128","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/archinte.1980.00330220019010","volume":"140","author":"LE Orr","year":"1980","unstructured":"Orr LE, McKernan JF, Bloome B (1980) Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Internal Med 140(11):1431\u20133","journal-title":"Arch Internal Med"},{"issue":"2","key":"9087_CR129","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0897190020972208","volume":"35","author":"V Parihar","year":"2022","unstructured":"Parihar V, Rogers A, Blain AM, Zacharias SRK, Patterson LL, Siyam MA-M (2022) Reduction in tamoxifen metabolites endoxifen and N-desmethyltamoxifen with chronic administration of low dose cannabidiol: a CYP3A4 and CYP2D6 drug interaction. J Pharm Pract 35(2):322\u20136","journal-title":"J Pharm Pract"},{"key":"9087_CR130","first-page":"104990912211430","volume":"9008229, atd","author":"LM Philpot","year":"2022","unstructured":"Philpot LM, Ramar P, Jatoi A, Rosedahl J, Canning R, Ebbert JO (2022) Cannabis in cancer survivors who report high impact chronic pain: findings from a 1500+ patient survey. Am J Hospice Palliative Care 9008229, atd:10499091221143098","journal-title":"Am J Hospice Palliative Care"},{"issue":"4","key":"9087_CR131","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.outlook.2021.01.012","volume":"69","author":"H Poghosyan","year":"2021","unstructured":"Poghosyan H, Noonan EJ, Badri P, Braun I, Young GJ (2021) Association between daily and non-daily cannabis use and depression among United States adult cancer survivors. Nurs Outlook 69(4):672\u2013685","journal-title":"Nurs Outlook"},{"issue":"12","key":"9087_CR132","doi-asserted-by":"crossref","first-page":"e27374","DOI":"10.1002\/pbc.27374","volume":"65","author":"S Polito","year":"2018","unstructured":"Polito S, MacDonald T, Romanick M, Jupp J, Wiernikowski J, Vennettilli A et al (2018) Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: a multicenter, retrospective review. Pediatr Blood Cancer 65(12):e27374","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"9087_CR133","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00256701","volume":"17","author":"M Pomeroy","year":"1986","unstructured":"Pomeroy M, Fennelly JJ, Towers M (1986) Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 17(3):285\u2013288","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"9087_CR134","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jpain.2012.01.003","volume":"13","author":"RK Portenoy","year":"2012","unstructured":"Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S et al (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13(5):438\u2013449","journal-title":"J Pain"},{"issue":"5","key":"9087_CR135","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1200\/JOP.17.00106","volume":"14","author":"D Portman","year":"2018","unstructured":"Portman D, Donovan KA (2018) Cannabinoid hyperemesis syndrome: a case report of a confounding entity in oncology care. J Oncol Practice 14(5):333\u2013334","journal-title":"J Oncol Practice"},{"issue":"5","key":"9087_CR136","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JOP.19.00720","volume":"16","author":"D Portman","year":"2020","unstructured":"Portman D, Donovan KA (2020) Case of pneumonitis associated with cannabis vaping and cancer immunotherapy. JCO Oncol Practice 16(5):245\u2013246","journal-title":"JCO Oncol Practice"},{"issue":"7","key":"9087_CR137","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00381-018-3830-x","volume":"34","author":"E Pralong","year":"2018","unstructured":"Pralong E, Maduri R, Daniel RT, Messerer M (2018) Cannabinoid-induced alteration of motor-evoked potentials (MEPs) prior to intradural spinal tumor removal: a nasty surprise. Child\u2019s Nervous Syst 34(7):1287\u20131289","journal-title":"Child's Nervous Syst"},{"issue":"4","key":"9087_CR138","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0009-9260(84)80088-4","volume":"35","author":"TJ Priestman","year":"1984","unstructured":"Priestman TJ, Priestman SG (1984) An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting. Clin Radiol 35(4):265\u2013266","journal-title":"Clin Radiol"},{"issue":"9","key":"9087_CR139","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1007\/s00520-022-07170-8","volume":"30","author":"NJ Raghunathan","year":"2022","unstructured":"Raghunathan NJ, Brens J, Vemuri S, Li QS, Mao JJ, Korenstein D (2022) In the weeds: a retrospective study of patient interest in and experience with cannabis at a cancer center. Supportive Care Cancer 30(9):7491\u20137497","journal-title":"Supportive Care Cancer"},{"issue":"10","key":"9087_CR140","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1089\/jpm.2018.0528","volume":"22","author":"M Reblin","year":"2019","unstructured":"Reblin M, Sahebjam S, Peeri NC, Martinez YC, Thompson Z, Egan KM (2019) Medical cannabis use in glioma patients treated at a comprehensive cancer center in Florida. J Palliat Med 22(10):1202\u20131207","journal-title":"J Palliat Med"},{"issue":"8","key":"9087_CR141","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3109\/10826088609027401","volume":"21","author":"RA Roffman","year":"1986","unstructured":"Roffman RA (1986) Stress inoculation training in the control of THC toxicities. Int J Addict 21(8):883\u2013896","journal-title":"Int J Addict"},{"issue":"3","key":"9087_CR142","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000065511","volume":"48","author":"S Russmann","year":"2002","unstructured":"Russmann S, Winkler A, Lovblad KO, Stanga Z, Bassetti C (2002) Lethal ischemic stroke after cisplatin-based chemotherapy for testicular carcinoma and cannabis inhalation. Eur Neurol 48(3):178\u2013180","journal-title":"Eur Neurol"},{"issue":"9","key":"9087_CR143","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1200\/JOP.18.00057","volume":"14","author":"CE Saadeh","year":"2018","unstructured":"Saadeh CE, Rustem DR (2018) Medical marijuana use in a community cancer center. J Oncol Practice 14(9):e566\u2013e578","journal-title":"J Oncol Practice"},{"issue":"3","key":"9087_CR144","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJM198001173020302","volume":"302","author":"SE Sallan","year":"1980","unstructured":"Sallan SE, Cronin C, Zelen M, Zinberg NE (1980) Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 302(3):135\u2013138","journal-title":"N Engl J Med"},{"issue":"16","key":"9087_CR145","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJM197510162931603","volume":"293","author":"SE Sallan","year":"1975","unstructured":"Sallan SE, Zinberg NE, Frei E 3rd (1975) Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293(16):795\u2013797","journal-title":"N Engl J Med"},{"issue":"4","key":"9087_CR146","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000493567","volume":"140","author":"N Sarid","year":"2018","unstructured":"Sarid N, Zada M, Lev-Ran S, Yashphe E, Givon I, Barzilai M et al (2018) Medical cannabis use by Hodgkin lymphoma patients: experience of a single center. Acta Haematol 140(4):194\u2013202","journal-title":"Acta Haematol"},{"issue":"101568867","key":"9087_CR147","doi-asserted-by":"crossref","first-page":"649555","DOI":"10.3389\/fonc.2021.649555","volume":"11","author":"J Schloss","year":"2021","unstructured":"Schloss J, Lacey J, Sinclair J, Steel A, Sughrue M, Sibbritt D et al (2021) A phase 2 randomised clinical trial assessing the tolerability of two different ratios of medicinal cannabis in patients with high grade gliomas. Front Oncol 11(101568867):649555","journal-title":"Front Oncol"},{"issue":"10","key":"9087_CR148","first-page":"177","volume":"118","author":"G Schmidt-Wolf","year":"2021","unstructured":"Schmidt-Wolf G, Cremer-Schaeffer P (2021) Interim results of the survey accompanying the prescription of cannabis-based medicines in Germany regarding dronabinol. Deutsches Arzteblatt Int 118(10):177\u2013178","journal-title":"Deutsches Arzteblatt Int"},{"issue":"7\u20138","key":"9087_CR149","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000524746","volume":"45","author":"H Senderovich","year":"2022","unstructured":"Senderovich H, Waicus S (2022) A case report on cannabinoid hyperemesis syndrome in palliative care: how good intentions can go wrong. Oncol Res Treat 45(7\u20138):438\u2013443","journal-title":"Oncol Res Treat"},{"issue":"4","key":"9087_CR150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/j.1552-4604.1984.tb01824.x","volume":"24","author":"VR Sheidler","year":"1984","unstructured":"Sheidler VR, Ettinger DS, Diasio RB, Enterline JP, Brown MD (1984) Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. J Clin Pharmacol 24(4):155\u2013159","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"9087_CR151","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1159\/000356446","volume":"6","author":"Y Singh","year":"2013","unstructured":"Singh Y, Bali C (2013) Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation. Case Rep Oncol 6(3):585\u2013592","journal-title":"Case Rep Oncol"},{"issue":"11\u201312","key":"9087_CR152","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/j.1552-4604.1984.tb02756.x","volume":"24","author":"JE Stambaugh Jr","year":"1984","unstructured":"Stambaugh JE Jr, McAdams J, Vreeland F (1984) Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. J Clin Pharmacol 24(11\u201312):480\u2013485","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"9087_CR153","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt1978234397","volume":"23","author":"M Staquet","year":"1978","unstructured":"Staquet M, Gantt C, Machin D (1978) Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 23(4):397\u2013401","journal-title":"Clin Pharmacol Ther"},{"issue":"2\u20133","key":"9087_CR154","first-page":"219","volume":"64","author":"N Steele","year":"1980","unstructured":"Steele N, Gralla RJ, Braun DW Jr, Young CW (1980) Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 64(2\u20133):219\u2013224","journal-title":"Cancer Treat Rep"},{"issue":"21","key":"9087_CR155","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2005.05.1847","volume":"24","author":"F Strasser","year":"2006","unstructured":"Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W et al (2006) Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabi. J Clin Oncol 24(21):3394\u20133400","journal-title":"J Clin Oncol"},{"issue":"2","key":"9087_CR156","first-page":"143","volume":"9","author":"RC Stuart-Harris","year":"1983","unstructured":"Stuart-Harris RC, Mooney CA, Smith IE (1983) Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy. Clin Oncol 9(2):143\u2013146","journal-title":"Clin Oncol"},{"issue":"6","key":"9087_CR157","first-page":"e26406","volume":"14","author":"KT Sura","year":"2022","unstructured":"Sura KT, Kohman L, Huang D, Pasniciuc SV (2022) Experience with medical marijuana for cancer patients in the palliative setting. Cureus 14(6):e26406","journal-title":"Cureus"},{"issue":"4","key":"9087_CR158","first-page":"289","volume":"20","author":"S Sutton","year":"1986","unstructured":"Sutton S, Lum BL, Torti FM (1986) Possible risk of invasive pulmonary aspergillosis with marijuana use during chemotherapy for small cell lung cancer. Drug Intell Clin Pharm 20(4):289\u2013291","journal-title":"Drug Intell Clin Pharm"},{"issue":"S1","key":"9087_CR159","doi-asserted-by":"crossref","first-page":"70S","DOI":"10.1002\/j.1552-4604.1981.tb02577.x","volume":"21","author":"DL Sweet","year":"1981","unstructured":"Sweet DL, Miller NJ, Weddington W, Senay E, Sushelsky L (1981) delta 9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study. J Clin Pharmacol 21(S1):70S\u20135S","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"9087_CR160","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3109\/10428190109097776","volume":"42","author":"M Szyper-Kravitz","year":"2001","unstructured":"Szyper-Kravitz M, Lang R, Manor Y, Lahav M (2001) Early invasive pulmonary aspergillosis in a leukemia patient linked to aspergillus contaminated marijuana smoking. Leuk Lymphoma 42(6):1433\u20131437","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"9087_CR161","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1634\/theoncologist.2018-0383","volume":"24","author":"T Taha","year":"2019","unstructured":"Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G (2019) Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. Oncologist 24(4):549\u2013554","journal-title":"Oncologist"},{"issue":"1","key":"9087_CR162","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/ayu.AYU_43_19","volume":"40","author":"SD Tavhare","year":"2019","unstructured":"Tavhare SD, Acharya R, Reddy RG, Dhiman KS (2019) Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: an open-label single arm clinical trial. Ayu. 40(1):34\u201343","journal-title":"Ayu."},{"issue":"10","key":"9087_CR163","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1089\/jpm.2022.0100","volume":"25","author":"C Tofthagen","year":"2022","unstructured":"Tofthagen C, Perlman A, Advani P, Ernst B, Kaur J, Tan W et al (2022) Medical marijuana use for cancer-related symptoms among Floridians: a descriptive study. J Palliat Med 25(10):1563\u20131570","journal-title":"J Palliat Med"},{"issue":"15 Supplement","key":"9087_CR164","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1212\/WNL.94.15_supplement.5302","volume":"94","author":"C Tschoe","year":"2020","unstructured":"Tschoe C, Johnson L, Giugliano A, Sarwal A (2020) Serotonin syndrome with exposure from tetrahydrocannabinol: a case report to highlight the side effects of increasing use of cbd products. Neurology 94(15 Supplement):5302","journal-title":"Neurology"},{"issue":"9","key":"9087_CR165","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1007\/s00520-018-4154-9","volume":"26","author":"JG Turcott","year":"2018","unstructured":"Turcott JG, del Rocio Guillen Nunez M, Flores-Estrada D, Onate-Ocana LF, Zatarain-Barron ZL, Barron F et al (2018) The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer 26(9):3029\u201338","journal-title":"Support Care Cancer"},{"issue":"8","key":"9087_CR166","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41416-021-01259-3","volume":"124","author":"C Twelves","year":"2021","unstructured":"Twelves C, Sabel M, Checketts D, Miller S, Tayo B, Jove M et al (2021) A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. Br J Cancer 124(8):1379\u20131387","journal-title":"Br J Cancer"},{"issue":"6","key":"9087_CR167","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/00000421-198512000-00014","volume":"8","author":"LB Tyson","year":"1985","unstructured":"Tyson LB, Gralla RJ, Clark RA, Kris MG, Bordin LA, Bosl GJ (1985) Phase 1 trial of levonantradol in chemotherapy-induced emesis. Am J Clin Oncol 8(6):528\u2013532","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"9087_CR168","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/1097-0142(19820815)50:4<636::AID-CNCR2820500404>3.0.CO;2-4","volume":"50","author":"JT Ungerleider","year":"1982","unstructured":"Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K (1982) Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 50(4):636\u2013645","journal-title":"Cancer"},{"issue":"2","key":"9087_CR169","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00000421-198504000-00006","volume":"8","author":"JT Ungerleider","year":"1985","unstructured":"Ungerleider JT, Sarna G, Fairbanks LA, Goodnight J, Andrysiak T, Jamison K (1985) THC or Compazine for the cancer chemotherapy patient\u2013the UCLA study Part II: Patient drug preference. Am J Clin Oncol 8(2):142\u20137","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"9087_CR170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/082585971202800110","volume":"28","author":"JGC van Hasselt","year":"2012","unstructured":"van Hasselt JGC, van den Heuvel MM, Schellens JHM, Beijnen JH, Brandsma D, Huitema ADR (2012) Severe cannabinoid intoxication in a patient with non-small-cell lung cancer. J Palliat Care 28(1):60\u201361","journal-title":"J Palliat Care"},{"issue":"2","key":"9087_CR171","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpainsymman.2014.05.018","volume":"49","author":"B Waissengrin","year":"2015","unstructured":"Waissengrin B, Urban D, Leshem Y, Garty M, Wolf I (2015) Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience. J Pain Symptom Manage 49(2):223\u2013230","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"9087_CR172","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jpainsymman.2005.11.007","volume":"30","author":"D Walsh","year":"2005","unstructured":"Walsh D, Kirkova J, Davis MP (2005) The efficacy and tolerability of long-term use of dronabinol in cancer-related anorexia: a case series. J Pain Symptom Manage 30(6):493\u2013495","journal-title":"J Pain Symptom Manage"},{"issue":"5\u20136","key":"9087_CR173","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/13554794.2017.1391294","volume":"23","author":"PP Warren","year":"2017","unstructured":"Warren PP, Bebin EM, Nabors LB, Szaflarski JP (2017) The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy. Neurocase 23(5\u20136):287\u2013291","journal-title":"Neurocase"},{"issue":"101652231","key":"9087_CR174","volume":"34","author":"EM Webster","year":"2020","unstructured":"Webster EM, Yadav GS, Gysler S, McNamara B, Black J, Tymon-Rosario J et al (2020) Prescribed medical cannabis in women with gynecologic malignancies: a single-institution survey-based study. Gynecol Oncol Reports 34(101652231):100667","journal-title":"Gynecol Oncol Reports"},{"issue":"1","key":"9087_CR175","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF00257422","volume":"11","author":"J Welsh","year":"1983","unstructured":"Welsh J, Stuart F, Sangster G, Milstead R, Kaye S, Cash H et al (1983) Oral levonantradol in the control of cancer chemotherapy-induced emesis. Cancer Chemother Pharmacol 11(1):66\u201367","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"9087_CR176","first-page":"353","volume":"10","author":"P Zaki","year":"2017","unstructured":"Zaki P, Blake A, Wolt A, Chan S, Zhang L, Wan A et al (2017) The use of medical cannabis in cancer patients. J Pain Manag 10(4):353\u2013362","journal-title":"J Pain Manag"},{"key":"9087_CR177","doi-asserted-by":"crossref","unstructured":"Zhou ES, Nayak MM, Chai PR, Braun IM. Cancer patient\u2019s attitudes of using medicinal cannabis for sleep. Journal of psychosocial oncology. 2021((Zhou, Nayak, Chai, Braun) Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, MA, Boston, United States(Zhou) Division of Sleep Medicine, Harvard Medical School, MA, Boston, United States(Chai) Division of Medical Toxic):1\u20137","DOI":"10.1080\/07347332.2021.1910396"},{"issue":"9308777, c6k","key":"9087_CR178","doi-asserted-by":"crossref","first-page":"102592","DOI":"10.1016\/j.ctim.2020.102592","volume":"56","author":"Y Zolotov","year":"2021","unstructured":"Zolotov Y, Eshet L, Morag O (2021) Preliminary assessment of medical cannabis consumption by cancer survivors. Complement Therapies Med 56(9308777, c6k):102592","journal-title":"Complement Therapies Med"},{"issue":"12","key":"9087_CR179","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1007\/s00520-021-06301-x","volume":"29","author":"DM Zylla","year":"2021","unstructured":"Zylla DM, Eklund J, Gilmore G, Gavenda A, Guggisberg J, VazquezBenitez G et al (2021) A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Supportive Care Cancer 29(12):7471\u20137478","journal-title":"Supportive Care Cancer"},{"issue":"7","key":"9087_CR180","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/jcm8070989","volume":"8","author":"JD Brown","year":"2019","unstructured":"Brown JD, Winterstein AG (2019) Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med 8(7):989","journal-title":"J Clin Med"},{"issue":"4","key":"9087_CR181","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/jcm9040919","volume":"9","author":"JD Brown","year":"2020","unstructured":"Brown JD (2020) Potential adverse drug events with tetrahydrocannabinol (THC) due to drug-drug interactions. J Clin Med 9(4):919","journal-title":"J Clin Med"},{"key":"9087_CR182","doi-asserted-by":"crossref","first-page":"1386263","DOI":"10.3389\/fpsyt.2024.1386263","volume":"15","author":"K Johnson","year":"2024","unstructured":"Johnson K, Weldon AJ, Burmeister MA (2024) Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen. Front Psychiatry 15:1386263","journal-title":"Front Psychiatry"},{"issue":"6","key":"9087_CR183","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/jcm9061925","volume":"9","author":"Z Latif","year":"2020","unstructured":"Latif Z, Garg N (2020) The impact of marijuana on the cardiovascular system: a review of the most common cardiovascular events associated with marijuana use. J Clin Med 9(6):1925","journal-title":"J Clin Med"},{"issue":"6","key":"9087_CR184","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.3390\/molecules28062791","volume":"28","author":"S Kitdumrongthum","year":"2023","unstructured":"Kitdumrongthum S, Trachootham D (2023) An individuality of response to cannabinoids: challenges in safety and efficacy of cannabis products. Molecules 28(6):2791","journal-title":"Molecules"},{"key":"9087_CR185","doi-asserted-by":"crossref","first-page":"1055481","DOI":"10.3389\/fpsyt.2022.1055481","volume":"13","author":"RT Smith","year":"2022","unstructured":"Smith RT, Gruber SA (2022) Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions. Front Psychiatry 13:1055481","journal-title":"Front Psychiatry"},{"issue":"1","key":"9087_CR186","first-page":"3","volume":"6","author":"MA Alsherbiny","year":"2018","unstructured":"Alsherbiny MA, Li CG (2018) Medicinal cannabis-potential drug interactions. Medicines (Basel) 6(1):3","journal-title":"Medicines (Basel)"},{"issue":"4","key":"9087_CR187","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.3390\/cimb45040228","volume":"45","author":"M Babayeva","year":"2023","unstructured":"Babayeva M, Loewy ZG (2023) Cannabis pharmacogenomics: a path to personalized medicine. Curr Issues Mol Biol 45(4):3479\u20133514","journal-title":"Curr Issues Mol Biol"},{"issue":"5","key":"9087_CR188","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.3390\/jcm11051154","volume":"11","author":"V Lopera","year":"2022","unstructured":"Lopera V, Rodr\u00edguez A, Amariles P (2022) Clinical relevance of drug interactions with cannabis: a systematic review. J Clin Med 11(5):1154","journal-title":"J Clin Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-09087-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-09087-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-09087-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T19:56:42Z","timestamp":1737403002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-09087-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":188,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["9087"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-09087-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The corresponding author (I.C.) is a research student and a non-practising pharmacist who works in the pharmaceutical industry. She has no past or present affiliations with any pharmaceutical companies that manufacture or distribute cannabis-based products. She has not received any grants or payments related to any cannabis-based products.Authors JHu and JHar have received payments, travel and\/or accommodation for providing expert advice about traditional, complementary and integrative medicine to industry, government bodies and non-government organisations. They have spoken at conferences and\/or provided consultations for which honoraria, registration, travel and\/or accommodation have been paid for by the organisers.Jennifer Hunter reports a relationship with Southern Cannabis Holdings (SCH) Research and NICM Health Research Institute, Western Sydney University that includes consulting fees.There are no competing interests associated with this publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"40"}}